Biohaven Ltd. (BHVN) Stock AnalysisBHVNBiohaven Ltd.

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (MoDE) and Targeted Removal of Aberrant Protein (TRAP) extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases, including obesity. Its pipeline includes TYK2/JAK1 Inhibitor (brain-penetrant), IgG Degrader, Gd-IgA1 TRAP Degrader, Taldefgrobep Alfa, Kv7 Activator, TRPM3 Antagonist FGFR3 ADC, CD30 ADC, Trop2 ADC +/- PD1, and others. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Biohaven Ltd (BHVN) is not a good buy right now due to significant regulatory risks and poor financial performance. The stock is currently priced at $12.08, with an RSI of 31.523 indicating oversold conditions. The company has reported consistent net losses, with a net income of -221,677,000 USD in Q1 2025 and a forward P/E ratio of 0, suggesting no earnings growth expectations. The recent FDA clinical hold on its epilepsy treatment has led to a 16% drop in stock price, highlighting ongoing uncertainties. The main risk is the FDA's clinical hold, which could further impact the stock's performance.

5 analysts cover BHVN: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.00.